Aspect Biosystems
Vancouver, British Columbia, Canada · Biotechnology, Health Care · 110 employees
Aspect Biosystems is a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat some of the most elusive diseases. Aspect’s bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these next-generation cell therapies by applying its full-stack tissue therapeutic platfor
Funding history
- Funding Round — $79.0M — Apr 2026
- Series series b — $115.0M — Jan 2025
Recent signals
- Apr 06, 2026: Raised $79.0M
- Jan 08, 2025: Aspect Biosystems partners with Dimension and Novo Nordisk in $115M funding round
- Jan 08, 2025: Aspect Biosystems Raises US$115 Million Series B Financing for Bioprinted Tissue Therapeutics
- Jan 08, 2025: Raised $115.0M in Series series b
- Jul 10, 2024: Aspect Biosystems Announces $200 Million Partnership with the Governments of Canada and British Columbia to Advance Development of Bioprinted Tissue Therapeutics
See plans & pricing → Track Aspect Biosystems’s funding, hiring, and signals — with verified contacts — on Fundz.